This CME-accredited OncoBlast activity uses case-based, ABIM-style questions to reinforce evidence-based clinical decision-making in gastrointestinal cancers. Participants will explore key advances in treatment selection and sequencing, biomarker-driven therapy, and evolving standards of care in GI malignancies. The interactive format is designed to challenge clinicians to synthesize clinical data, patient factors, and guideline recommendations in real-world scenarios.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Ronan Hsieh (MD)
As a faculty at the University of Washington Fred Hutchinson Cancer Center, I lead many clinical and translational studies in the field of gastrointestinal oncology. I focus my research on drug development using novel trial design and cancer models such as tissue slice culture and organoids, which I collaborate with translational scientists at Fred Hutch. Fun facts - I grew up in Taiwan, so you can hear me promoting bubble tea as the best beverage in the world all the time. I like hiking and cycling, and naturally I love Seattle as my new home town in the U.S.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Financial Support Ineligible company: Curio Science Topic: Honorarium Attribution: Self Type of financial relationship: Professional Services Ineligible company: Bristol Myers Squibb Topic: Advisory Board Attribution: Self Type of financial relationship: Professional Services Ineligible company: Bayer Topic: Research Support Attribution: Self Type of financial relationship: Professional Services Ineligible company: Janssen Topic: Research Support Attribution: Self Type of financial relationship: Travel Ineligible company: Medscape Attribution: Self Type of financial relationship: Travel Ineligible company: Merck
- Medical oncologists
- Radiation oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Target Audience
- Apply recent clinical trial data to personalize neoadjuvant and adjuvant strategies in colorectal and rectal cancer.
- Integrate molecular profiling and biomarker-driven treatment selection in advanced GI cancers.
- Evaluate therapeutic options and sequencing for metastatic GI malignancies based on efficacy, safety, and patient-specific factors.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: